Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
ID: 350493Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350493

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-308.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)" through a cooperative agreement aimed at enhancing cancer research and education for underserved populations. This initiative seeks to establish sustainable partnerships between institutions serving health disparity populations and NCI-designated Cancer Centers, focusing on increasing research capacity, promoting workforce diversity, and improving outreach efforts. The program is critical for addressing cancer health disparities and ensuring that underserved communities benefit from comprehensive cancer initiatives. Interested applicants can apply for funding up to $1.7 million for two institutions or $2.2 million for three institutions over a maximum period of five years, with applications due by October 10, 2025. For more information, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-308.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-308-Full-Announcement.html
    PAR-23-308.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), announces the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) funding opportunity (PAR-23-308). This initiative aims to create sustainable partnerships between institutions serving underserved health disparity populations and NCI-designated Cancer Centers, thereby enhancing cancer research capacity, promoting diversity, and improving outreach and education efforts. Partnerships will include multiple core components to support cancer research, education, and community engagement. Applications are invited from a variety of organizations, including higher education institutions, non-profits, and local governments, with specific eligibility criteria for partnership institutions. The funding cycle begins December 15, 2023, with a budget cap of $1.7 million for two institutions and $2.2 million for three, over a maximum period of five years. Key components of the application include Administrative, Planning and Evaluation, Research Education, and Outreach and Engagement Cores, alongside Full and Pilot Research Projects. The program emphasizes the importance of diverse collaborations to address cancer health disparities and ensure that underserved populations benefit from comprehensive cancer programs and research initiatives.
    Similar Opportunities
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced an Administrative Supplement funding opportunity aimed at enhancing cancer disparities research through the initiative PAR-22-114. This program encourages collaborations between seasoned cancer researchers and those focused on cancer disparities, with the goal of addressing adverse differences in cancer outcomes among racial/ethnic minorities and underserved populations. The funding supports the expansion of existing NCI-funded research projects to include feasibility studies on various cancer types, with a total funding amount of $2.55 million available for up to 10 awards, each with a budget limit of $150,000 in direct costs over a 12-month period. Interested applicants must submit their proposals by January 23, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH), under the funding opportunity RFA-CA-24-020. This initiative aims to establish a network of multidisciplinary programs dedicated to translational cancer research, specifically targeting prevention, early detection, treatment, and diagnosis in underserved populations affected by cancer. The program requires applicants to propose at least three research projects supported by comprehensive infrastructure, including various cores such as Administrative, Shared Resources, Developmental Research Program, and Career Enhancement Program, with a maximum budget request of $1.6 million annually over five years. Interested applicants must submit their proposals by September 27, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The total funding available for this opportunity is approximately $80 million, expected to be distributed among around four awards.
    Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish sites for early-phase cancer prevention clinical trials. The initiative aims to develop and conduct trials that assess the safety and efficacy of various preventive agents and interventions targeting specific biological processes associated with cancer development, with a focus on recruiting high-risk participants and conducting multi-institutional studies. This funding underscores the importance of advanced research in cancer prevention, with a total funding amount of $8.75 million annually to support five awards over six years, each with a budget not exceeding $1.375 million. Interested applicants must submit a letter of intent by August 23, 2024, and a complete application by September 30, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research," aimed at advancing cancer research through the use of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Biorepository. This initiative encourages applications that leverage high-quality, pre-diagnostic biospecimens and associated data to explore cancer risk factors and develop early detection biomarkers, emphasizing the unique characteristics of the PLCO resources. Eligible applicants include a diverse range of institutions, including historically black colleges, tribal colleges, and various community organizations, with no cost-sharing requirement. The application deadline is October 11, 2024, and interested parties can find more information and contact details at the NIH website or via email at OERWebmaster03@od.nih.gov.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting exploratory research projects in cancer communication. This initiative focuses on three key areas: developing new cancer communication surveillance strategies, creating rapid intervention methods, and establishing multilevel communication models to enhance cancer prevention and control efforts. The NIH emphasizes the importance of utilizing contemporary methodologies, such as social media analysis and artificial intelligence, to address misinformation and improve health literacy in cancer care. Eligible applicants can receive funding of up to $275,000 for a maximum duration of two years, with applications due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the detailed announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html.